Pharma BD Deal Intelligence
Frames the $14/share, $1.4B Cadence buy as Mallinckrodt's bid to broaden its specialty hospital footprint beyond controlled-substance generics, anchored on…
Notes the deal's strategic fit, calling Ofirmev a high-growth differentiated pain product expected to be immediately accretive to Mallinckrodt's FY2014 EPS and…
Documents Senate pricing scrutiny of Mallinckrodt's post-acquisition Ofirmev list price hike from $14.75 to $35.40 per vial, raising sustainability questions…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mallinckrodt acquired Cadence Pharmaceuticals for $14.00 per share in cash, totaling approximately $1.4B. The deal added IV acetaminophen Ofirmev—on formulary at 2,350+ U.S. hospitals—to Mallinckrodt's specialty hospital portfolio. Tender offer expired March 18 and the deal closed March 19, 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. (this deal) | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2014 deals · Mallinckrodt plc deals · Other deals